Gosta Labs, a Helsinki-based HealthTech company innovating in the oncology sector, has closed a €7.5 million Seed round to scale its AI operating system for complex medical specialties.
The round was led by Voima Ventures, with participation from COR Group, the Aho family, and both existing and new investors, including Reaktor and a group of notable angel investors. This follows a €1.7 million pre-Seed round in 2024 and brings the company’s total funding to nearly €10 million.
“We started Gosta Labs to bring AI to support extremely complex medical specialties like oncology, to give care teams back time and headspace for their patients by taking on the documentation work that drains their day,” says Lauri Sippola, CEO and co-founder of Gosta Labs.
In 2025, several European HealthTech startups working in oncology and adjacent medical AI fields have secured notable funding rounds – providing sector context for Gosta Labs’ raise.
Swiss-based CGC Genomics raised €1.7 million to advance its regulated GenAI platform for interpreting cancer genome data. London’s Perci Health secured €4 million to scale its AI-driven virtual cancer clinic. Barcelona-based Sycai Medical obtained €3 million to further develop its AI medical device for early cancer detection, while Leiden’s BIMINI Biotech raised €3 million to progress its haematological cancer therapeutics.
In this context, Gosta Labs’ Seed round represents one of the larger early-stage financings in the oncology-AI segment this year, contributing to a sector total of roughly €11.7 million in comparable 2025 funding announcements.
Gosta’s Finland headquarters also stands out, as Finland does not appear among the other 2025 oncology-AI fundings, underscoring its relative position in the region.
“This funding helps us bring our trusted AI assistant to oncology teams around the world and deepen our medical device grade product and AI foundation, so every patient encounter can be safer, more personal, and less burdened by administration,” adds Sippola.
Founded in 2023 by Lauri Sippola and Henri Viertolahti, who previously founded Kaiku Health (acquired by Elekta in 2020), Gosta Labs is developing an AI operating system for complex medical specialties, like oncology, enabling more efficient, precise, and personalised care across the entire patient journey. Gosta Labs currently partners with healthcare providers in Finland, Switzerland, the Baltics, and Australia.
The company’s team combines AI scientists with experienced oncology and MedTech leaders, including Chief Medical Officer Dr Lionel Hadjadjeba and Chief Operating Officer Reetta Arokoski.
“This technology is already reshaping our clinical workflows. The ability to produce structured, accurate notes instantly and classify key clinical parameters automatically frees oncologists to spend their time where it matters most – with their patients. In practice, this has already cut documentation time by over two-thirds for each patient visit at our cancer centre,” says Dr Razvan Popescu, Medical Director at Tumor Center Aargau and the lead investigator in the study.
Cancer care is becoming increasingly complex.
As per data provided by the company – by 2050, more than 35 million new cancer cases are expected to be diagnosed across over 100 different types of cancer. Meanwhile, Gosta Labs highlights that clinicians spend several hours a day on administrative work within fragmented systems and unstructured clinical data, while multidisciplinary teams must make fast, high-stakes decisions regarding an ever-growing number of personalised treatment options.
Gosta Labs aims to address these challenges with an oncology-focused AI operating system that transforms every patient visit into high-quality structured data in real time.
The system summarises and visualises patient journeys, automates clinical documentation, and captures structured clinical data relevant to patient care. It also reportedly improves quality of care by assessing key clinical parameters for each treatment pathway and automatically linking decisions to international guidelines.
“Gosta Labs’ key team members combine proven startup execution, deep domain expertise and top notch AI capabilities. They’ve done it before and know what good looks like, which is an essential for any startup team,” said Jussi Sainiemi, Partner at Voima Ventures. “There’s a lot of hype around AI but Gosta delivers the value it promises and customers love the product.”
The first real-world results from the Gosta AI Operating System were presented at the ESMO 2025 Congress, a global oncology conference.
Results suggest that the oncology-focused system generates high-quality oncology consultation notes in real time, structured according to institutional standards. It also automatically classifies Performance Status and CTCAE toxicity grades.
Oncologists were reportedly able to complete follow-up visit documentation in a median time of under two minutes, reducing their documentation burden and enabling them to spend more time with patients.
Read the orginal article: https://www.eu-startups.com/2025/11/as-cancer-cases-surge-toward-35-million-by-2050-finlands-gosta-labs-raises-e7-5-million-to-ease-oncology-workloads/
